Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00313781
Previous Study | Return to List | Next Study

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00313781
Recruitment Status : Completed
First Posted : April 12, 2006
Results First Posted : April 11, 2013
Last Update Posted : April 11, 2013
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE April 10, 2006
First Posted Date  ICMJE April 12, 2006
Results First Submitted Date  ICMJE January 18, 2013
Results First Posted Date  ICMJE April 11, 2013
Last Update Posted Date April 11, 2013
Study Start Date  ICMJE May 2006
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 5, 2013)
Percentage of Participants With Prostate Specific Antigen (PSA) Best Response [ Time Frame: Baseline, Day 1 and Day 15 of each cycle, end of treatment (up to 28 days post last dose) and follow-up (monthly, up to 150 days post last dose) ]
Percentage of participants with PSA best response of either PSA normalization (PN) or partial PSA response (PR) relative to the total number of participants evaluable for response. PN was defined as PSA =< 0.2 nanogram/milliliter (ng/ml) on 2 successive evaluations at least 3 weeks apart and no imaging or clinical evidence of disease progression. PP was defined as >= 50% decrease in PSA from baseline on 2 successive evaluations at least 3 weeks apart and no imaging or clinical evidence of disease progression.
Original Primary Outcome Measures  ICMJE
 (submitted: April 10, 2006)
Antitumor efficacy measured as Objective Responses using PSA Working Group and RECIST criteria. Determined at the end of study.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 5, 2013)
  • Progression Free Survival (PFS) [ Time Frame: Baseline, Day 15 of each cycle and follow-up (monthly, up to 150 days post last dose) ]
    PFS was defined as the time from randomization to first event of disease progression. Disease progression events were defined as the following: PSA progression,objective disease progression as per RECIST, death, and discontinuation of treatment due to symptomatic deterioration. PSA progression was defined as the time-point of PSA progression on 2 successive evaluations taken 1 week apart after dosing in cycle 3.
  • Human Anti-human Antibody (HAHA) at Baseline (Day 1 of Cycle 1) [ Time Frame: Baseline (Day 1 of Cycle 1) ]
    Levels of HAHA in serum were detected at baseline.
  • Human Anti-human Antibody (HAHA) at the Last Follow-up Visit [ Time Frame: The last follow-up visit (150 days post last dose) ]
    Levels of HAHA in serum were detected at the last follow-up visit.
  • Population PK Parameters of CP-751,871 [ Time Frame: Days 1, 8 and 15 of each cycle and last follow-up visit (150 days post last dose) ]
    Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for CP-751,871 and to determine inter-individual and residual variability in population clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured CP-751,871 concentrations
  • Total Number of Circulation Tumor Cells (CTCs) [ Time Frame: Baseline, prior to dosing in odd numbered cycles (ie. Cycle 1, 3, 5, etc) and end of treatment (up to 28 days post last dose) ]
    Blood samples were collected and processed to enumerate the number of total CTCs via Veridex CellSearch technology in which CTCs were identified based on cell surface positive epithelial cell adhesion molecule (EpCAM) and cytokeratin staining.
  • Total Number of the Insulin Like Growth Factor Receptor Type 1 (IGF-1R) Positive CTCs [ Time Frame: Baseline, prior to dosing in odd numbered cycles (ie. Cycle 1, 3, 5, etc) and end of treatment (up to 28 days post last dose) ]
    Blood samples were collected to enumerate the number of total IGF-1R positive CTCs via Veridex CellSearch technology in which CTCs were identified based on cell surface positive EpCAM and cytokeratin staining. A separate CellSave tube of cells was also collected and processed with cell surface staining of IGF-1R to enumerate surfaces of IGF-1R-positive CTCs.
  • Quality of Life Measured by the Functional Assessment of Cancer Treatment-Prostate (FACT-P) [ Time Frame: Baseline, Cycle 1 to Cycle 10 before drug administration and end of treatment (up to 28 days post last dose) ]
    The FACT-P was a 39-item participant questionnaire which assesses physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items were scored from 0 (not at all) to 4 (very much). The total FACT-P score ranged from 0-156, with higher scores representing a better QoL with fewer symptoms. A score of 156 represented the best outcome.
  • Pain Measured by the Modified Brief Pain Inventory-Short Form (mBPI-sf Modified Pfizer) [ Time Frame: Baseline, Cycle 1 to Cycle 10 before drug administration and end of treatment (up to 28 days post last dose) ]
    The mBPI-sf was a self administered questionnaire developed to assess pain severity and pain interference with functional activities during a 24-hour period prior to evaluation. For the worst pain item of the mBPI-sf scale (11 point Likert scale; range: 0 [no pain] to 10 [pain as bad as you can imagine]), participants were asked to rate their pain by marking an "X" in one of the 10 boxes that best described their pain at its worst in the last 24 hours post surgery and at least 12 hours after discontinuation of the peripheral nerve block or neuraxial block.
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for CP-751,871 [ Time Frame: Days 1, 8 and 15 of each cycle and last follow-up visit (150 days post last dose) ]
    Area under the plasma concentration versus time curve from time zero to time of last quantifiable concentration.
  • Maximum Observed Plasma Concentration (Cmax) for CP-751,871 [ Time Frame: Days 1, 8 and 15 of each cycle and last follow-up visit (150 days post last dose) ]
  • Minimum Observed Plasma Trough Concentration (Cmin) for CP-751,871 [ Time Frame: Days 1, 8 and 15 of each cycle and last follow-up visit (150 days post last dose) ]
  • Area Under the Curve From Time Zero to End of Dosing Interval (AUC0-tau) for CP-751,871 [ Time Frame: Days 1, 8 and 15 of each cycle and last follow-up visit (150 days post last dose) ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 10, 2006)
Safety,pharmacokinetics,pharmacodynamics of CP-751,871/docetaxel/prednisone
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
Official Title  ICMJE A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of CP-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer
Brief Summary To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prostatic Neoplasms
Intervention  ICMJE
  • Drug: CP-751,871
    CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
  • Drug: docetaxel
    Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
  • Drug: prednisone
    Prednisone is administered at a dose of 5 mg twice daily.
Study Arms  ICMJE
  • Experimental: A
    For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
    Interventions:
    • Drug: CP-751,871
    • Drug: docetaxel
    • Drug: prednisone
  • Active Comparator: B
    Interventions:
    • Drug: docetaxel
    • Drug: prednisone
Publications * de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 26, 2011)
204
Original Enrollment  ICMJE
 (submitted: April 10, 2006)
120
Actual Study Completion Date  ICMJE December 2011
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of metastatic, progressive hormone refractory prostate cancer
  • Adequate bone marrow, liver and kidney function

Exclusion Criteria:

  • Previous treatment with chemotherapy
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Germany,   Spain,   Switzerland,   United Kingdom,   United States
Removed Location Countries Netherlands
 
Administrative Information
NCT Number  ICMJE NCT00313781
Other Study ID Numbers  ICMJE A4021011
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP